Characteristic | N (%) |
---|---|
Age (y) | |
Median | 61 |
Range | 41-91 |
Gender | |
Male | 62 |
Female | 8 |
Primary site | |
Oral cavity | 8 |
Oropharynx | 31 |
Hypopharynx | 17 |
Larynx | 10 |
Nasopharynx | 3 |
Unknown primary | 1 |
Tumor stage | |
T0 | 1 |
T1 | 5 |
T2 | 22 |
T3 | 25 |
T4 | 17 |
Nodal stage | |
N0 | 18 |
N1 | 16 |
N2a | 3 |
N2b | 20 |
N2c | 8 |
N3 | 5 |
Overall stage | |
I | 1 |
II | 15 |
III | 9 |
IV | 45 |
Radiotherapy | |
Step and Shoot IMRT | 65 |
Volumetric Modulated Arc Therapy | 5 |
Chemotherapy | |
Concurrent | |
Cisplatin | 22 |
Carboplatin/5-Fu | 7 |
Cetuximab | 12 |
Induction + concurrent | 7 |
No chemotherapy | 22 |